Clinical Trial Update: Clinical Trial of Ridaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma (MK-8669-007 AM6) [Phase 2]

View source ↗

Summary

A Phase 2 trial (MK-8669-007 AM6) evaluated ridaforolimus versus progestin or chemotherapy for advanced endometrial cancer and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• Ridaforolimus (ridaforolimus)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Endometrial Cancer | Phase 2 | Status: COMPLETED